Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for Chronic Subdural Hematoma Recurrence
NCT03845322Phase 1Withdrawn
- Sponsor
- The University of New Mexico
- Start
- Dec 2018
- Primary completion
- Feb 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic subdural hematoma (CSDH) comparing Curcumin with Placebo (2 arms). Primary endpoint: Measurements by CT of subdural hematoma volume change at 6 months. Planned start Dec 2018; status: withdrawn.
02
Drugs
curcumin
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT03845322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845322.